| Literature DB >> 35775040 |
Nityanand Jain1, I-Chun Hung2, Hitomi Kimura3, Yi Lin Goh4, William Jau5, Khoa Le Anh Huynh6, Deepkanwar Singh Panag1, Ranjit Tiwari7, Sakshi Prasad8, Emery Manirambona9, Tamilarasy Vasanthakumaran10, Tan Weiling Amanda4, Ho-Wei Lin5, Nikhil Vig11, Nguyen Thanh An12, Emmanuel Uwiringiyimana9, Darja Popkova1, Ting-Han Lin5, Minh Anh Nguyen13, Shivani Jain14, Tungki Pratama Umar15, Mohamed Hoosen Suleman16, Elnur Efendi1, Chuan-Ying Kuo5, Sikander Pal Singh Bansal11, Sofja Kauškale1, Hui-Hui Peng5, Mohit Bains11, Marija Rozevska1, Thang Huu Tran17, Meng-Shan Tsai5, Suvinai Jiraboonsri18, Ruo-Zhu Tai5, Zeeshan Ali Khan19, Dang Thanh Huy20, Supitsara Kositbovornchai18, Ching-Wen Chiu5, Thi Hien Hau Nguyen12, Hsueh-Yen Chen5, Thanawat Khongyot21, Kai-Yang Chen5, Dinh Thi Kim Quyen17, Jennifer Lam22, Kadek Agus Surya Dila23, Ngan Thanh Cu17, My Tam Huynh Thi24, Le Anh Dung12, Kim Oanh Nguyen Thi25, Hoai An Nguyen Thi25, My Duc Thao Trieu17, Yen Cao Thi26, Thien Trang Pham25, Koya Ariyoshi27,28, Chris Smith27,29, Nguyen Tien Huy2,27.
Abstract
Background: Tackling the spread of COVID-19 remains a crucial part of ending the pandemic. Its highly contagious nature and constant evolution coupled with a relative lack of immunity make the virus difficult to control. For this, various strategies have been proposed and adopted including limiting contact, social isolation, vaccination, contact tracing, etc. However, given the heterogeneity in the enforcement of these strategies and constant fluctuations in the strictness levels of these strategies, it becomes challenging to assess the true impact of these strategies in controlling the spread of COVID-19.Entities:
Keywords: COVID-19; Cities; Delta variant; Global response; Management; Provinces; Swiss Cheese; Testing; Transmission
Year: 2022 PMID: 35775040 PMCID: PMC9217141 DOI: 10.1016/j.lansea.2022.100031
Source DB: PubMed Journal: Lancet Reg Health Southeast Asia ISSN: 2772-3682
Characteristics of investigated cities/provinces and the source of confirmed daily cases.
| Sr. No. | City/Provinces | Country | Type | Population | Data source for daily confirmed COVID-19 cases |
|---|---|---|---|---|---|
| 1. | Bangkok | Thailand (Asia) | Major Outbreak | 5.5 million | |
| 2. | Gauteng | South Africa (Africa) | Major Outbreak | 15.5 million | |
| 3. | Ho Chi Minh City | Vietnam (Asia) | Major Outbreak | 3.5 million | |
| 4. | Jakarta | Indonesia (Asia) | Major Outbreak | 10.6 million | |
| 5. | London | UK (Europe) | Major Outbreak | 7.6 million | |
| 6. | Manila City | Philippines (Asia) | Controlled outbreak | 1.6 million | |
| 7. | New Delhi | India (Asia) | Major Outbreak | 10.9 million | |
| 8. | New York City | USA (America) | Major Outbreak | 8.2 million | |
| 9. | Singapore | Singapore (Asia) | Controlled Outbreak | 5.9 million | |
| 10. | Tokyo | Japan (Asia) | Major Outbreak | 8.3 million |
Estimated rounded-off population statistics were collected from Worldometer (https://www.worldometers.info/) and/or official government sources.
COVID-19 outbreak characteristics during the investigated period for the cities/provinces included in the study.
| City/Provinces | Duration of the outbreak (in days) | Peak daily cases reported (on date) | Total number of confirmed cases | Confirmed cases per 100,000 population |
|---|---|---|---|---|
| Bangkok | 155 | 5161 (13th Aug) | 426,155 | 7748.27 |
| Gauteng | 132 | 16,102 (3rd July) | 632,925 | 4083.39 |
| Ho Chi Minh City | 107 | 8499 (3rd Sept) | 430,186 | 12,291.03 |
| Jakarta | 160 | 14,619 (11th July) | 677,805 | 6394.39 |
| London | 190 | 7817 (15th July) | 788,348 | 10,373.00 |
| Manila City | 01 | 1177 (2nd April) | 75,978 | 4748.63 |
| New Delhi | 66 | 28,395 (20th April) | 814,397 | 7471.53 |
| New York City | 181 | 6603 (4th Jan) | 518,811 | 6326.96 |
| Singapore | 43 | 5324 (27th Oct) | 139,775 | 2369.07 |
| Tokyo | 86 | 5908 (13th Aug) | 320,407 | 3860.33 |
Duration of outbreak is defined as the number of days with equal to or greater than 1000 daily confirmed positive COVID-19 cases between 1st January 2021 and 31st October 2021.
Total number of confirmed cases is sum of total daily confirmed positive COVID-19 cases between 1st January 2021 and 31st October 2021.
Figure 1Trend graph showing the daily confirmed COVID-19 cases from January 2021 to October 2021 for cities/provinces with major outbreaks (green) and controlled outbreaks (yellow) with the red line indicating 7-day moving average. The peak highest daily number of confirmed cases is highlighted in the graph. (a) Bangkok; (b) Gauteng; (c) Ho Chi Minh City; (d) Jakarta; (e) London; (f) New Delhi; (g) New York City; (h) Tokyo; (i) Manila City and (j) Singapore. Note that the X-axis shows the date in DD.MM.YYYY format whilst the Y-axis shows the number of confirmed daily positive cases.
Figure 2The Population-level Swiss Cheese Model for COVID-19 transmission. Each cheese slice indicates specific barriers for protection and prevention with holes representing breaches (or failures) in the implementation of the specific barrier - (1) Planning, swiftly acting, and adapting to outbreaks; (2) Rapid enforcement of public health measures (like mask wearing, social distancing); (3) Sufficient testing capacity; (4) Proper isolation of the confirmed patients; (5) Robust identification and isolation measures for close contacts (contact tracing); (6) Cluster identification and mitigation to prevent high co-worker and household transmission rates; (7) Sufficient healthcare resources (like beds, oxygen, respirators); and (8) Vaccination promotion. Some of the barriers are co-enforceable like contact tracing and cluster identification (blue arrow). With widespread breaches in multiple barriers, the risk of viral transmission increases manyfold (black arrow), which allows for easy spread of the virus amongst the community (red arrow); ultimately leading to loss of lives and livelihood.
Distribution of nature and duration of lockdowns.
| Cities/Provinces | Hard Lockdown | Mild Lockdown | ||
|---|---|---|---|---|
| Duration (in days) | % Days of outbreak | Duration (in days) | % Days of outbreak | |
| Bangkok | 123 | 79% | 32 | 21% |
| Gauteng | 28 | 31% | 62 | 69% |
| Ho Chi Minh City | 69 | 64% | 39 | 36% |
| Jakarta | 0 | 0% | 160 | 100% |
| London | 0 | 0% | 190 | 100% |
| Manila City | 0 | 0% | Followed a bubble strategy called NCR+ | |
| New Delhi | 43 | 65% | Follows locality-wise lockdown strategy | |
| New York City | 0 | 0% | 181 | 100% |
| Singapore | 30 | 70% | 13 | 30% |
| Tokyo | 0 | 0% | 86 | 100% |
Hard lockdowns were defined as an all stay at home restriction with only essential business open whilst a mild lockdown was defined whereby work and travel were permitted with valid reasons.
Measures implemented for restriction monitoring.
| Cities/Provinces | Police patrolling to ensure containment | Hotlines/Apps for violation reporting | Independent COVID-19 task force |
|---|---|---|---|
| Bangkok | Yes, only during night curfew daily | Yes | Yes |
| Gauteng | Yes | Yes | Yes |
| Ho Chi Minh City | Yes, only during hard lockdown | No | No |
| Jakarta | Yes, closure of multiple main streets | Yes | Yes |
| London | No patrolling | Yes | Yes |
| Manila City | Yes, door-to-door suspected COVID-19 case search | Yes | No |
| New Delhi | Yes, maintaining containment areas | Yes | Yes |
| New York City | No patrolling | Yes | No |
| Singapore | No patrolling | Yes | Yes |
| Tokyo | No patrolling | No | Yes |
Descriptive findings regarding the mass testing and contact tracing strategy in individual cities/provinces between January and October 2021.
| Cities/Provinces | No. of laboratory tests conducted | Average No. of daily tests conducted | No. of tests per 1000 population | No. of total laboratory positive cases | Cases per 1000 population | Total test positivity rate |
|---|---|---|---|---|---|---|
| Bangkok | - | - | - | 426155 | 77.48 | - |
| Gauteng | 3715555 | 12222 | 239.71 | 632925 | 40.83 | 17.03% |
| Ho Chi Minh City | - | - | - | 430186 | 122.91 | - |
| Jakarta | 6065249 | 19952 | 572.19 | 677805 | 63.94 | 11.12% |
| London | 19028110 | 62593 | 2503.70 | 788348 | 103.73 | 04.14% |
| Manila City | 2317228 | 7622 | 1448.27 | 75978 | 47.49 | 03.28% |
| New Delhi | 20619994 | 67828 | 1891.74 | 814397 | 74.72 | 03.95% |
| New York City | 23787885 | 78250 | 2900.96 | 518811 | 63.27 | 02.18% |
| Singapore | 15398343 | 50652 | 2609.89 | 139775 | 23.69 | 00.91% |
| Tokyo | 2948400 | 9699 | 355.23 | 320407 | 38.60 | 10.87% |
For Bangkok and Ho Chi Minh City, only national country-wide statistics for number of tests conducted were available.
WHO had previously suggested a positivity rate of around 3–12% as a general benchmark of adequate testing, along with recommending that test positivity should remain at 5% or lower for 14 days before regions reopen (Source: https://globalhealth.harvard.edu/evidence-roundup-why-positive-test-rates-need-to-fall-below-3/).
The total test positivity rate is calculated for the period between January and October 2021 and gives the overall positivity rate. It doesn't represent the individual fluctuations in specific weeks during these months.
Healthcare resources available in the investigated cities/provinces.
| Cities/Provinces | No. of Public Hospitals | No. of Private hospitals | Total No. of hospitals | No. of ICU beds | No. of hospital beds | No. of doctors per 1000 inhabitants (country-level) |
|---|---|---|---|---|---|---|
| Bangkok | 48 | 116 | 164 | 262 | 69682 | 0.81 |
| Gauteng | 39 | 83 | 122 | 1462 | 30934 | 0.91 |
| Ho Chi Minh City | 82 | 46 | 128 | 370 | 30000 | 0.82 |
| Jakarta | 49 | 144 | 193 | 921 | 23081 | 0.43 |
| London | - | - | 134 | - | 37878 | 2.81 |
| Manila NCR | 16 | 43 | 59 | 1264 | 9421 | 0.60 |
| New Delhi | 37 | 43 | 80 | 2222 | 9581 | 0.86 |
| New York City | - | - | 70 | 2059 | 15338 | 2.61 |
| Singapore | 14 | 9 | 23 | 163 | 13614 | 2.29 |
| Tokyo | - | - | 650 | 1100 | 125700 | 2.41 |
Note: The data presented doesn't include field hospitals, make-shift care centers, hotels, or other temporary facilities that were made available for use in the management of Covid-19 patients.
Population that was vaccinated against COVID-19 in the investigated cities.
| Cities/Provinces | Date of start of mass vaccination | Partially Vaccinated (Dose 1) | Fully Vaccinated (Dose 1+2) | ||
|---|---|---|---|---|---|
| No. of people | % City population | No. of people | % City population | ||
| Bangkok | 07.06.2021 | 13.61 million | 91.62% | 10.40 million | 70.01% |
| Gauteng | 17.05.2021 | 3.98 million | 25.68% | 2.07 million | 13.35% |
| Ho Chi Minh City | 10.07.2021 | - | > 95% | - | 79.00% |
| Jakarta | 08.06.2021 | 10.10 million | 95.28% | 7.80 million | 74.28% |
| London | 18.06.2021 | 6.05 million | 79.60% | 5.46 million | 71.84% |
| Manila NCR | 11.10.2021 | 9.08 million | 67.26% | 7.90 million | 58.52% |
| New Delhi | 01.05.2021 | 13.05 million | - | 7.43 million | 68.17% |
| New York City | 06.04.2021 | 6.14 million | 74.87% | 5.50 million | 67.07% |
| Singapore | 03.02.2021 | 4.68 million | 79.32% | 4.49 million | 76.10% |
| Tokyo | 21.06.2021 | 10.27 million | 74.20% | 9.85 million | 71.20% |
Note that vaccination rates are approximate and include all approved COVID-19 vaccines and eligible age groups in the respective cities. The number of people represents the total number of people who were vaccinated from the respective date of start of vaccination to 31st October 2021. Additionally, the data also includes non-residents of the city who were vaccinated in the city (reliable distribution is not available). Hence, % City population may not be precise, however, does provide an approximate estimation of the vaccination coverage in the city for inter-city comparisons.
Mass vaccination refers to the period from which all adults aged 16+ or 18+ (based on different countries) were eligible for vaccination.
For New Delhi, % City population vaccinated with first dose cannot be estimated due to number of doses administered surpasses total population. The vaccination coverage for Bangkok and Tokyo was obtained from official sources since the number of doses exceeded the total population of the city (https://ddc.moph.go.th/covid19-dashboard/?dashboard=province and https://stopcovid19.metro.tokyo.lg.jp/en/).
For Manila, the statistics shown are for Manila NCR (National Capital Region, Metro Manila) with population of 13.5 million.
For Ho Chi Minh City, only percentages are available from the official sources (https://luatvietnam.vn/y-te/bao-cao-1730-bc-byt-2021-tinh-hinh-dich-va-cong-tac-chong-tac-phong-chong-covid-19-ngay-30-10-2021-211811-d6.html).
Covid-19 vaccines approved (emergency use authorization) in the investigated cities and provinces (date of approval# in dd/mm/yy format).
| Cities/Provinces | mRNA based | Non-replicating viral vector | Inactivated | |||||
|---|---|---|---|---|---|---|---|---|
| Pfizer/BioNTech Comirnaty | Moderna Spikevax | AstraZeneca/Oxford Vaxzervria | J&J Janssen | Gamaleya Sputnik V | Sinopharm Covilo | SinoVac CoronaVac | Bharat Biotech Covaxin | |
| Bangkok | 24.06.21 | 13.05.21 | 20.01.21 | 25.03.21 | Pending | 28.05.21 | 22.02.21 | Pending |
| Gauteng | 16.03.21 | Pending | 23.01.21 | 22.02.21 | Unknown | 07.02.21 | 03.07.21 | Unknown |
| Ho Chi Minh City | 12.06.21 | 29.06.21 | 29.01.21 | 15.07.21 | 23.03.21 | 04.06.21 | Unknown | 10.11.21 |
| Jakarta | 15.07.21 | 02.07.21 | 09.03.21 | 07.09.21 | 24.08.21 | 30.04.21 | 11.01.21 | Unknown |
| London | 02.12.20 | 08.01.21 | 30.12.20 | 28.05.21 | Unknown | Unknown | Unknown | Unknown |
| Manila NCR | 11.03.21 | 05.05.21 | 28.01.21 | 20.04.21 | 19.03.21 | 08.06.21 | 07.04.21 | 20.04.21 |
| New Delhi | Unknown | 29.06.21 | 03.01.21 | 07.08.21 | 13.04.21 | Unknown | Unknown | 03.01.21 |
| New York City | 11.12.20 | 19.12.20 | Pending | 27.02.21 | Unknown | Unknown | Unknown | Pending |
| Singapore | 14.12.20 | 03.02.21 | Unknown | Unknown | Unknown | Unknown | 23.10.21 | Unknown |
| Tokyo | 15.02.21 | 21.05.21 | 21.05.21 | Unknown | Unknown | Unknown | Unknown | Unknown |
Note that date of approval of vaccine doesn't indicate that the vaccine was made available for use for public. Additionally, date of approval doesn't correspond to the date of start of administration of vaccine. The date of approval is representative for the entire country and for adult populations (Source: https://covid19.trackvaccines.org/). The date of approval may vary by 1-2 days from official government sources (due to variations in news reporting and official dates).
Pending status indicates that the vaccine had not approved been approved in the period studied in the present study (up to November 2021). Unknown status indicates no information is available regarding the application status and approval status for emergency use authorization in the country.
AstraZeneca/Oxford Vaxzevria also includes its analogue produced by Serum Institute of India Covishield.
Gamaleya Sputnik V doesn't include the later developed Sputnik Light.
Vietnam (Ho Chi Minh City) had also approved Center for Genetic Engineering and Biotechnology (CIGB) Abdala on 18.09.21.
Indonesia (Jakarta) had also approved Anhui Zhifei Longcom Zifivax on 07.10.21, Serum Institute of India COVOVAX on 01.11.2021, CanSino Convidecia on 07.09.21 and BioKangtai KconecaVac on 31.10.21.
India (New Delhi) had also approved Zydus Cadila ZyCoV-D on 20.08.21 and Sputnik Light on 17.05.21.
‡Philippines (Manila NCR) had also approved Sputnik Light on 23.08.21 and Serum Institute of India COVOVAX on 17.11.21.